Drug class: Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors Mechanism of Action Alectinib is a tyrosine kinase inhibitor (TKI) that selectively targets anaplastic lymphoma kinase (ALK), a transmembrane receptor protein involved in regulating cell growth. In ALK‑positive cancers, a chromosomal translocation fuses unrelated genes to form a mutant 80 kDa chimeric protein with uncontrolled tyrosine kinase activity. This leads to automated intermolecular transphosphory